__timestamp | Eli Lilly and Company | Novo Nordisk A/S |
---|---|---|
Wednesday, January 1, 2020 | 153244924560 | 992801077492.3201 |
Friday, January 1, 2021 | 250521319860.00003 | 1681508787391.9998 |
Saturday, January 1, 2022 | 329891098240 | 2129286754102.3198 |
Sunday, January 1, 2023 | 524266006679.99994 | 3131247795972.8003 |
Unleashing insights
In the past five years, the pharmaceutical titans Eli Lilly and Novo Nordisk have showcased remarkable growth in market capitalization. As of 2023, Novo Nordisk's market cap surged by an impressive 243% from its 2019 value, reaching a staggering 3.1 trillion. Meanwhile, Eli Lilly experienced a robust 330% increase, climbing to 527 billion. This growth reflects the companies' strategic innovations and expanding influence in the global healthcare sector. While Novo Nordisk leads with a market cap nearly six times that of Eli Lilly, both companies have demonstrated resilience and adaptability in a rapidly evolving market. Investors and industry watchers should keep a keen eye on these powerhouses as they continue to shape the future of pharmaceuticals.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters